Die Möglichkeiten der medikamentösen Antikoagulation werden zusehends vielfältiger. Im
anästhesiologisch-intensivmedizinischen Bereich gilt es darüber hinaus spezielle …

Although heparin has been a cornerstone of treatment for the prevention of thrombosis, it is
limited by its adverse effects and unpredictable bioavailability. Direct thrombin inhibitors are …

Purpose Anticoagulation is part of the daily routine of intensive care physicians. As the
possibilities of pharmacological anticoagulation are becoming more numerous and diverse …

Decades of research have been devoted to developing effective, safe, and convenient
anticoagulant agents. In recent years, much emphasis has been placed on the development …

Traditional anticoagulants used clinically for prevention and treatments of thromboembolic
disease are unfractionated heparin and warfarin. A narrow therapeutic window and high …

Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated
heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary …

Antithrombin drugs represent a wide group of natural agents, recombinant agents equivalent
to some of the naturally occurring proteins, and synthetic agents. This group of drugs is …

The parenteral direct thrombin inhibitors (DTIs) act independent of antithrombin and are
typically used in situations where unfractionated heparin (UFH) is not recommended such as …

Thrombin is the key effector enzyme responsible for the final step in thrombus formation.
Because of the central role it plays in thrombus generation, propagation, and stabilization …

Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to
thrombin and block its interaction with its substrates. Four parenteral DTIs have been …